Patents Examined by Ronald T Niebauer
  • Patent number: 12162955
    Abstract: The present invention relates to series of peptidomimetic compounds selectively targeting CBX8 of polycomb chromobox protein homolog proteins. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases involved CBX8 pharmacology, including various cancers and leukemia, by administering therapeutically effective amounts of such compound alone or together with other therapeutics, are within the scope of this disclosure.
    Type: Grant
    Filed: January 31, 2023
    Date of Patent: December 10, 2024
    Assignee: Purdue Research Foundation
    Inventors: Casey J. Krusemark, Emily C. Dykhuizen, Sijie Wang
  • Patent number: 12162954
    Abstract: The present invention relates to a method for preparing etelcalcetide hydrochloride (etelcalcetide HCL). A first peptide is de-protected and cleaved from a solid support by a first solution system, for obtaining a second peptide, followed by coupling an activated L-Cys-OH to the second peptide in the second solution system for forming a TFA salt of etelcalcetide that is not or hardly dissolved in the second solution system. After purification by column chromatography, the TFA salt of etelcalcetide can be converted to etelcalcetide HCL using a third solution system that excludes hydrogen chloride during a real-time monitoring salt exchange step. The present method provides a simplified process and the etelcalcetide HCL with high purity and yield, for being advantageously applied in mass production of etelcalcetide HCL.
    Type: Grant
    Filed: July 18, 2022
    Date of Patent: December 10, 2024
    Assignee: KRISAN BIOTECH Co., Ltd.
    Inventors: Ya-Chun Chang, Shih-Wei Li
  • Patent number: 12139556
    Abstract: The present invention relates to natural or natural-like analogues of insect kinin neuropeptide [Hy]-RQKTVFSSWG-[NH2] (SEQ ID NO:2) having activity against insects, for example hemipteran, dipteran, lepidopteran and/or blattodean insects, such as aphids, moths and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.
    Type: Grant
    Filed: October 23, 2023
    Date of Patent: November 12, 2024
    Assignee: Solasta Bio Limited
    Inventors: Julian A. T. Dow, Shireen A. Davies, Yousef Abul-Haija, Lewis Archibald
  • Patent number: 12139557
    Abstract: A synthetic peptide sp2 has the amino acid sequence shown in SEQ ID No: 1. sp2 has obvious anti-tumor growth activity on xenograft tumours such as subcutaneous human pancreatic cancer, human cervical cancer, and human ovarian cancer in nude mice, with a dose-effect and time-effect relation; and has the effect of delaying metastasis and prolonging the survival time of nude mouse having in situ transplantation of human pancreatic cancer and lung adenocarcinoma. After the animals were given intravenous injection of sp2 at a dose of 2000 mg/kgBW, no toxicity reaction and death were observed. The applications of sp2 also include: (1) preventing and/or treating of tumor; (2) inhibiting proliferation and/or growth and/or invasion of tumor cells; (3) enhancing the anti-tumor immune response; (4) inducing tumor cell differentiation; (5) preparing anti-tumor drugs; (6) inhibiting tumor telomerase activity; and (7) regulating the tumor cell cycle.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: November 12, 2024
    Assignee: TAIAN CITY QIHANG BIOTECHNOLOGY CO.
    Inventors: Wanqin Zhang, Yintian Li, Xuewen Ji, Limei Zhao
  • Patent number: 12129312
    Abstract: Disclosed in the present invention are a peptide compound, an application thereof, and a composition containing the same. Provided in the present invention are a peptide compound represented by formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a solvate thereof, a crystal form thereof, or a prodrug thereof. The compound has good stability and good activity.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 29, 2024
    Assignee: XDCEXPLORER (SHANGHAI) CO., LTD.
    Inventors: Yan Wang, Yvonne Angell, Yun Wu, Manhua Li, Yonghan Hu
  • Patent number: 12129222
    Abstract: It is an object of the present invention to introduce carboxylic acid-functionalities suitable for coupling into the denatonium structure by means of simple synthesis, namely the synthesis of bitter principle derivatives based on the denatonium structure according to formula 1: For example, according to the invention, lidocaine derivatives may be reacted with carboxylated benzyl halogenides. The carboxylated denatonium derivatives of the present invention are especially applied in medicine, biology, medical engineering as well as cosmetics, the pharmaceutical, chemical, and foodstuff industry.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 29, 2024
    Assignee: Julius-Maximilians-Universitaet
    Inventors: Ralf Wyrwa, Claudia Rode, Thomas Seemann, Lorenz Meinel, Jennifer Ritzer, Matthias Schnabelrauch
  • Patent number: 12076367
    Abstract: A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced in vitro by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: September 3, 2024
    Assignee: Pharma Cinq, LLC
    Inventors: Tianci Luo, Jun Zhang
  • Patent number: 12076368
    Abstract: The present invention relates to methods for treatment or prevention of liver, biliary tract, and pancreatic disorders by administering one or more defensins. Included within the scope of the disclosure is also treatment of certain metabolic disorders.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: September 3, 2024
    Assignee: Novozymes A/S
    Inventors: Peter Nordkild, Soren Kjaerulff
  • Patent number: 12072338
    Abstract: The invention provides pharmaceutical compositions comprising at least a portion of a chemokine receptor or a G-protein coupled receptor. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis, rheumatoid arthritis and asthma. The invention also provides peptides that may be used individually, in combination with, or in combination with other therapeutic agents such as steroid, non-steroid anti-inflammatory drug, immune modulator or immune suppressor.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: August 27, 2024
    Assignee: PROTAGONISTS LTD.
    Inventors: Chai Ezerzer, Nicholas Harris
  • Patent number: 12065511
    Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: August 20, 2024
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventors: D. Travis Wilson, Marc W. Andersen, Elizabeth Mead
  • Patent number: 12064514
    Abstract: The present invention is directed to peptisomes, including nanopeptisomes, which have a perfluorocarbon liquid core containing a perfluorocarbon liquid and a cargo, such as a therapeutically active agent, dispersed in the perfluorocarbon. liquid, and a plurality of amphiphilic peptide molecules surrounding the perfluorocarbon liquid core, wherein the amphiphilic peptide is represented by Formula (I) HB-CL-HP wherein HB is a fluorinated hydrophobic block, such as a fluorinated hydrophobic amino acid sequence, CL is a cross-linking motif, and HP is a hydrophilic amino acid sequence. The present invention is also directed to methods of use of the amphiphilic peptides and peptisomes, such as nanopeptisomes, to deliver a cargo, such as a therapeutically active agent, to a cell, Q wherein the cell may be in vitro, ex vivo, or in vivo.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 20, 2024
    Assignees: THE PENN STATE RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH
    Inventors: Joel P. Schneider, Scott H. Medina
  • Patent number: 12037417
    Abstract: The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: July 16, 2024
    Assignee: Kagoshima University
    Inventors: Yuji Ito, Yoshinari Shoyama, Akio Hayashi, Norihito Nakata
  • Patent number: 12024571
    Abstract: The present specification provides an anti-EpoR peptide. A peptide having the structure represented by formula (I): V-SCH(A1)(A2)(A3)(A4)(A5)(A6)v(A7)(A8)-X2 (wherein X1 is the amino terminal side of the peptide; X2 is the carboxy terminal side of the peptide; A1 is M or F, phenylglycine or phenethylglycine optionally substituted by a halogen atom or a hydroxyl group; A2 is A, d-alanine or G; A3 is P, homoproline or A; A4 is M, L, A or I; A5 is T or A; A6 is M or W, F, Y, ?-homotryptophan, ?-naphthylalanine, ?-naphthylalanine, or quinolylalanine optionally substituted by methyl or a halogen atom; A7 is C, homocysteine, or penicillamine; and A8 is K, R or absent) is provided.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: July 2, 2024
    Assignee: Epo-Med Inc.
    Inventors: Hiroyuki Kouji, Yoshiko Yasuda, Akira Katoh, Hiroshi Ochi
  • Patent number: 12018095
    Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: June 25, 2024
    Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki Endo, Yukihito Ishizaka, Akira Ishiguro, Tomoki Takashina, Takashi Yamamoto, Tetsushi Sakuma
  • Patent number: 12012466
    Abstract: The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: June 18, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Alanine, Julien Beignet, Konrad Bleicher, Bernhard Fasching, Hans Hilpert, Taishan Hu, Dwight MacDonald, Stephen Jackson, Sabine Kolczewski, Carsten Kroll, Adrian Schaeublin, Hong Shen, Theodor Stoll, Helmut Thomas, Amal Wahhab, Claudia Zampaloni
  • Patent number: 11999805
    Abstract: Specific and broad-spectrum inhibitory peptides to CRISPR Cas9 variants (SpyCas9, SauCas9, and CjeCas9) are disclosed. A method of making and using these peptides with therapeutic CRISPR Cas9 (to improve desired targeting) or against harmful CRISPR Cas9 components (already active in a patient) is also disclosed. The peptides combined with a delivery system is also disclosed.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: June 4, 2024
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Brooke Nicole Harmon, Yooli Kim Light, Mary Bao Tran-Gyamfi, Joseph S. Schoeniger, Edwin A. Saada, Kenneth L. Sale
  • Patent number: 11992514
    Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: May 28, 2024
    Assignee: MAIA PHARMACEUTICALS, INC.
    Inventor: Srikanth Sundaram
  • Patent number: 11952433
    Abstract: The present disclosure relates to a heterochiral peptide complex, a self-assembled intermediate thereof, an alignment medium composition used for nuclear magnetic resonance spectroscopy residual dipolar coupling (NMR-RDC) measurement, which includes the same, and a method for NMR measurement for a biomolecule. Since the heterochiral peptide complex contains a ?-sheet peptide and has superior structural stability against environmental factors such as heat, acidity and ionic strength, it is applicable as an alignment medium for measuring RDC for various biomolecules.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: April 9, 2024
    Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Yong-Beom Lim, Hye Soo Lee
  • Patent number: 11939399
    Abstract: A synthetic peptide sp4 has an amino acid sequence shown in SEQ ID NO: 1. As the sole effective ingredient in the antitumor efficacy test, it has a significant inhibitory effect on both the tumor volume and tumor weight of human osteosarcoma MG-63 in nude mice and has a significant dose-effect and time-effect relationship. There is no difference between the relative tumor growth rate T/C (%) of sp4 and that of the positive control group of Paclitaxel. The safety of sp4 is that its maximal tolerated dose for intravenous administration is 700 mg/kgBW. Sp4 has clear targets of pharmacological effects, while having efficacy in vivo, it also has an inhibitory effect on tumor telomerase, has an arrest on G1 phase of the tumor cell cycle, and inhibits the high expressions of tumor PD-L1 and CD47. The present disclosure relates to multiple uses of sp4, especially in the preparation of a class of antitumor drugs.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: March 26, 2024
    Assignee: TAIAN CITY QIHANG BIOTECHNOLOGY CO.
    Inventors: Wanqin Zhang, Yintian Li, Xuewen Ji, Limei Zhao
  • Patent number: 11939398
    Abstract: The invention relates to neurodegenerative disorders, and in particular to novel peptides, peptidomimetics, compositions, therapies and methods for treating such conditions, for example Alzheimer's disease.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: March 26, 2024
    Assignee: Neuro-Bio Ltd
    Inventors: Susan Greenfield, Sara Garcia-Rates, Jesus Seco Moral, Roger Prades Cosano